Recurrent FOSL1 rearrangements in desmoplastic fibroblastoma.
FOS
FOSL1
desmoplastic fibroblastoma
gene rearrangement
targeted sequencing
Journal
The Journal of pathology
ISSN: 1096-9896
Titre abrégé: J Pathol
Pays: England
ID NLM: 0204634
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
revised:
02
11
2022
received:
23
09
2022
accepted:
23
11
2022
pubmed:
26
11
2022
medline:
17
1
2023
entrez:
25
11
2022
Statut:
ppublish
Résumé
The FOS gene family has been implicated in tumourigenesis across several tumour types, particularly mesenchymal tumours. The rare fibrous tumour desmoplastic fibroblastoma is characterised by overexpression of FOSL1. However, previous studies using cytogenetic and molecular techniques did not identify an underlying somatic change involving the FOSL1 gene to explain this finding. Prompted by an unusual index case, we report the discovery of a novel FOSL1 rearrangement in desmoplastic fibroblastoma using whole-genome and targeted RNA sequencing. We investigated 15 desmoplastic fibroblastomas and 15 fibromas of tendon sheath using immunohistochemistry, in situ hybridisation and targeted RNA sequencing. Rearrangements in FOSL1 and FOS were identified in 10/15 and 2/15 desmoplastic fibroblastomas respectively, which mirrors the pattern of FOS rearrangements observed in benign bone and vascular tumours. Fibroma of tendon sheath, which shares histological features with desmoplastic fibroblastoma, harboured USP6 rearrangements in 9/15 cases and did not demonstrate rearrangements in any of the four FOS genes. The overall concordance between FOSL1 immunohistochemistry and RNA sequencing results was 90%. These findings illustrate that FOSL1 and FOS rearrangements are a recurrent event in desmoplastic fibroblastoma, establishing this finding as a useful diagnostic adjunct and expanding the spectrum of tumours driven by FOS gene family alterations. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Identifiants
pubmed: 36426824
doi: 10.1002/path.6038
pmc: PMC10107450
doi:
Substances chimiques
USP6 protein, human
EC 3.4.19.12
Ubiquitin Thiolesterase
EC 3.4.19.12
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
119-124Subventions
Organisme : Department of Health
Pays : United Kingdom
Organisme : Cancer Research UK
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 223135/Z/21/Z
Pays : United Kingdom
Informations de copyright
© 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Références
Diagn Pathol. 2016 Aug 11;11(1):75
pubmed: 27515856
J Biol Chem. 2017 Dec 29;292(52):21282-21290
pubmed: 29150442
Nat Commun. 2018 Jun 1;9(1):2150
pubmed: 29858576
Lab Invest. 2012 May;92(5):735-43
pubmed: 22411068
Mod Pathol. 2021 Oct;34(10):1876-1888
pubmed: 34088995
Oncogene. 2001 Nov 8;20(51):7563-72
pubmed: 11709728
Mol Cell Biol. 2007 Jun;27(11):3936-50
pubmed: 17371847
Genes Chromosomes Cancer. 2014 Nov;53(11):951-9
pubmed: 25043949
Mol Cell Biol. 1983 May;3(5):914-21
pubmed: 6306448
J Pathol. 2014 Apr;232(5):534-40
pubmed: 24374978
Cancer Res. 2017 Nov 1;77(21):e31-e34
pubmed: 29092934
Oncogene. 2001 Apr 30;20(19):2401-12
pubmed: 11402336
Genes Chromosomes Cancer. 2015 Sep;54(9):565-74
pubmed: 26173738
Histopathology. 2016 Dec;69(6):1012-1020
pubmed: 27442992
Genome Res. 2021 Mar;31(3):448-460
pubmed: 33441414
Int J Mol Sci. 2022 Jan 28;23(3):
pubmed: 35163444
In Vivo. 2021 Jan-Feb;35(1):69-73
pubmed: 33402451
Cell. 2000 Sep 29;103(1):29-40
pubmed: 11051545
Br J Cancer. 2022 Jul;127(1):137-144
pubmed: 35449451
Am J Surg Pathol. 2019 Dec;43(12):1661-1667
pubmed: 31490237
Mod Pathol. 2007 Apr;20(4):482-96
pubmed: 17334349
Immunol Rev. 2005 Dec;208:126-40
pubmed: 16313345